Navigation Links
Rescheduled Webcast: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011
Date:9/8/2011

CARLSBAD, Calif., Sept. 8, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:What:

Data from Mipomersen's Open-Label Extension Study presented at ESCWhen:

Monday, September 12, 2011 at 12:00 p.m. ET / 9:00 a.m. PTWhere:

www.isispharm.comHow:

Live on the Internet.  Simply log onto our Web site listed above. If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 24 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Boost For Japanese Pharma Market as UBM Announces Rescheduled Japan Pharma and Bio Events
2. "IVD Technology" Announces Upcoming Webcast: Omics and the Development of IVDs
3. IVD Technology Announces Educational Lecture Webcast: Challenges in Clinical Lab Automation and IVD Instrumentation Development
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 23, 2017  Therabron Therapeutics, Inc., a clinical-stage ... in respiratory care, today announced that the European ... has granted Orphan Drug Designation for Therabron,s CG367 ... Syndrome (BOS).  "We are pleased to ... to treat patients diagnosed with BOS following lung ...
(Date:1/23/2017)... , Jan. 23, 2017 LifeVac, the ... a blocked airway and prevented choking deaths, welcomes ... advocate to the LifeVac team as Official Spokesperson. ... join the LifeVac team," said Arthur Lih , ... to represent LifeVac and his mission to raise awareness ...
(Date:1/23/2017)... 23, 2017 Research and Markets has announced the ... - Product - Forecast to 2025" report to their offering. ... Report Highlights: ... trends to identify the investment opportunities Market forecasts till ... Key market trends across the business segments, Regions and Countries ...
Breaking Medicine Technology:
(Date:1/22/2017)... ... , ... Medical lab testing through hospitals and other traditional methods ... will take days to arrive to the end customer, having to travel through medical ... lab tests, bypassing the cost and delay of traditional means. Now all employees of ...
(Date:1/21/2017)... ... 2017 , ... Salveo for life, a company that distributes an effervescent lime-flavored ... States as part of its presence to expand its market reach. , Using a ... productions of nasty toxins as a result of drinking alcohol, eliminating those toxins quickly, ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... Seamild, the ... on the futuristic vision of its owner and founder. As Oat is recognized globally ... to everybody he knows personally as he believes it is a move to sow ...
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s ... electrifying line-up of events for its annual meeting “Coming Home 2017,” an activity-packed ... “Coming Home 2017” will be held on Friday January 27 through Sunday, January ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa ... in Petaluma, located at 167 Lynch Creek Way. The Petaluma office features three ... medicine and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons ...
Breaking Medicine News(10 mins):